Randomized controlled trial of insulin detemir versus NPH for the treatment of pregnant women with diabetes

What Was Tested

This randomized controlled trial paper looks at Insulin Detemir and NPH Insulin (isophane).

Patients were instructed to test BG 4 times a day (fasting and 2-hour postprandial).

Who Took Part

According to the abstract, 88 patients were involved.

The age groups tagged for this paper are teenagers, young adults and adults, women only.

Exclusion criteria were type 1 diabetes, age <18 years, and insulin allergy.

The primary outcome was overall mean BG during insulin treatment; secondary outcomes included overall mean postprandial and fasting BG, median number of weeks to achieve GC, percent of patients with overall GC, maternal weight gain, perinatal/neonatal outcomes, and number of hypoglycemic events.

How the Study Was Run

The design is described as randomized.

The patients were allocated by chance, so the Insulin Detemir group and the comparison group should start out alike.

A per protocol analysis was performed.

What Was Measured

Topics PubMed links to this paper include Diabetes Mellitus, Type 2, Diabetes, Gestational, Hypoglycemic Agents, Insulin Detemir, Insulin, Isophane, Insulin, Long-Acting and Intention to Treat Analysis.

Author keywords: gestational diabetes, insulin neutral protamine Hagedorn and pregnancy.

What This Means in Plain Language

The paper is a randomized study of Insulin Detemir and NPH Insulin (isophane) in 88 patients.

The abstract goes on to report its results in about 9 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2015 (American journal of obstetrics and gynecology), a journal based in United States.

More context: the Insulin Detemir compound page and the NPH Insulin (isophane) compound page, all human trials.